OptimizeRx (OPRX) Competitors

OptimizeRx logo
$7.31 +0.37 (+5.33%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$7.32 +0.01 (+0.07%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPRX vs. EVH, CTEV, AMWL, DH, and HCAT

Should you buy OptimizeRx stock or one of its competitors? OptimizeRx's main competitors and comparable companies include Evolent Health (EVH), Claritev (CTEV), American Well (AMWL), Definitive Healthcare (DH), and Health Catalyst (HCAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does OptimizeRx compare to Evolent Health?

OptimizeRx (NASDAQ:OPRX) and Evolent Health (NYSE:EVH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, OptimizeRx had 13 more articles in the media than Evolent Health. MarketBeat recorded 14 mentions for OptimizeRx and 1 mentions for Evolent Health. OptimizeRx's average media sentiment score of 0.13 beat Evolent Health's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OptimizeRx
0 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Evolent Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

76.5% of OptimizeRx shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Comparatively, 1.5% of Evolent Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

OptimizeRx presently has a consensus price target of $11.21, indicating a potential upside of 53.41%. Evolent Health has a consensus price target of $6.04, indicating a potential upside of 53.07%. Given OptimizeRx's higher probable upside, research analysts plainly believe OptimizeRx is more favorable than Evolent Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OptimizeRx
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Evolent Health
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.64

OptimizeRx has higher earnings, but lower revenue than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$109.43M1.26$5.13M$0.2529.24
Evolent Health$1.88B0.24-$534.51M-$4.54N/A

OptimizeRx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Evolent Health has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

OptimizeRx has a net margin of 5.33% compared to Evolent Health's net margin of -21.67%. OptimizeRx's return on equity of 9.58% beat Evolent Health's return on equity.

Company Net Margins Return on Equity Return on Assets
OptimizeRx5.33% 9.58% 7.47%
Evolent Health -21.67%-6.07%-1.23%

Summary

OptimizeRx beats Evolent Health on 13 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Claritev?

Claritev (NYSE:CTEV) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Claritev has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Claritev currently has a consensus target price of $44.83, indicating a potential upside of 101.77%. OptimizeRx has a consensus target price of $11.21, indicating a potential upside of 53.41%. Given Claritev's higher probable upside, analysts clearly believe Claritev is more favorable than OptimizeRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Claritev
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
OptimizeRx
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

87.2% of Claritev shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 7.4% of Claritev shares are owned by insiders. Comparatively, 7.5% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

OptimizeRx has a net margin of 5.33% compared to Claritev's net margin of -27.05%. OptimizeRx's return on equity of 9.58% beat Claritev's return on equity.

Company Net Margins Return on Equity Return on Assets
Claritev-27.05% N/A -5.74%
OptimizeRx 5.33%9.58%7.47%

In the previous week, Claritev had 2 more articles in the media than OptimizeRx. MarketBeat recorded 16 mentions for Claritev and 14 mentions for OptimizeRx. Claritev's average media sentiment score of 1.34 beat OptimizeRx's score of 0.13 indicating that Claritev is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Claritev
9 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OptimizeRx
0 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

OptimizeRx has lower revenue, but higher earnings than Claritev. Claritev is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Claritev$965.41M0.39-$284.28M-$16.42N/A
OptimizeRx$109.43M1.26$5.13M$0.2529.24

Summary

OptimizeRx beats Claritev on 9 of the 14 factors compared between the two stocks.

How does OptimizeRx compare to American Well?

American Well (NYSE:AMWL) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

American Well currently has a consensus price target of $12.30, suggesting a potential upside of 11.30%. OptimizeRx has a consensus price target of $11.21, suggesting a potential upside of 53.41%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than American Well.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
American Well
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
OptimizeRx
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

In the previous week, OptimizeRx had 13 more articles in the media than American Well. MarketBeat recorded 14 mentions for OptimizeRx and 1 mentions for American Well. American Well's average media sentiment score of 0.55 beat OptimizeRx's score of 0.13 indicating that American Well is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
American Well
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OptimizeRx
0 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

American Well has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

OptimizeRx has lower revenue, but higher earnings than American Well. American Well is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Well$211.23M0.90-$95.70M-$3.44N/A
OptimizeRx$109.43M1.26$5.13M$0.2529.24

OptimizeRx has a net margin of 5.33% compared to American Well's net margin of -27.03%. OptimizeRx's return on equity of 9.58% beat American Well's return on equity.

Company Net Margins Return on Equity Return on Assets
American Well-27.03% -24.32% -17.91%
OptimizeRx 5.33%9.58%7.47%

56.0% of American Well shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 12.8% of American Well shares are owned by company insiders. Comparatively, 7.5% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

OptimizeRx beats American Well on 12 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Definitive Healthcare?

Definitive Healthcare (NASDAQ:DH) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

98.7% of Definitive Healthcare shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 17.1% of Definitive Healthcare shares are held by company insiders. Comparatively, 7.5% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

OptimizeRx has lower revenue, but higher earnings than Definitive Healthcare. Definitive Healthcare is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definitive Healthcare$241.52M0.59-$138.93M-$1.50N/A
OptimizeRx$109.43M1.26$5.13M$0.2529.24

In the previous week, OptimizeRx had 11 more articles in the media than Definitive Healthcare. MarketBeat recorded 14 mentions for OptimizeRx and 3 mentions for Definitive Healthcare. Definitive Healthcare's average media sentiment score of 0.23 beat OptimizeRx's score of 0.13 indicating that Definitive Healthcare is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definitive Healthcare
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
OptimizeRx
0 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Definitive Healthcare has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

OptimizeRx has a net margin of 5.33% compared to Definitive Healthcare's net margin of -69.18%. OptimizeRx's return on equity of 9.58% beat Definitive Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Definitive Healthcare-69.18% 4.35% 1.84%
OptimizeRx 5.33%9.58%7.47%

Definitive Healthcare currently has a consensus price target of $1.47, suggesting a potential upside of 9.81%. OptimizeRx has a consensus price target of $11.21, suggesting a potential upside of 53.41%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than Definitive Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definitive Healthcare
3 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
OptimizeRx
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Summary

OptimizeRx beats Definitive Healthcare on 10 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Health Catalyst?

OptimizeRx (NASDAQ:OPRX) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

OptimizeRx has higher earnings, but lower revenue than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$109.43M1.26$5.13M$0.2529.24
Health Catalyst$272.21M0.36-$177.97M-$2.83N/A

OptimizeRx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, OptimizeRx had 9 more articles in the media than Health Catalyst. MarketBeat recorded 14 mentions for OptimizeRx and 5 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.52 beat OptimizeRx's score of 0.13 indicating that Health Catalyst is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OptimizeRx
0 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Health Catalyst
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 7.5% of OptimizeRx shares are held by insiders. Comparatively, 19.4% of Health Catalyst shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

OptimizeRx currently has a consensus target price of $11.21, indicating a potential upside of 53.41%. Health Catalyst has a consensus target price of $2.01, indicating a potential upside of 55.68%. Given Health Catalyst's higher possible upside, analysts clearly believe Health Catalyst is more favorable than OptimizeRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OptimizeRx
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Health Catalyst
1 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.83

OptimizeRx has a net margin of 5.33% compared to Health Catalyst's net margin of -74.24%. OptimizeRx's return on equity of 9.58% beat Health Catalyst's return on equity.

Company Net Margins Return on Equity Return on Assets
OptimizeRx5.33% 9.58% 7.47%
Health Catalyst -74.24%-4.84%-2.02%

Summary

OptimizeRx beats Health Catalyst on 10 of the 16 factors compared between the two stocks.

Get OptimizeRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPRX vs. The Competition

MetricOptimizeRxHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$131.21M$1.92B$7.72B$11.67B
Dividend YieldN/A3.89%2.47%4.53%
P/E Ratio29.2439.4132.3627.90
Price / Sales1.265.208.285.57
Price / Cash7.0515.5120.8521.62
Price / Book1.034.594.443.72
Net Income$5.13M-$19.09M$3.51B$394.03M
7 Day Performance-17.59%-7.41%-4.69%-4.67%
1 Month Performance-16.36%-7.56%-5.66%-7.21%
1 Year Performance-48.74%-11.73%-1.17%-7.05%

OptimizeRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPRX
OptimizeRx
3.7425 of 5 stars
$7.31
+5.3%
$11.21
+53.4%
-48.2%$131.21M$109.43M29.24105
EVH
Evolent Health
2.3427 of 5 stars
$4.89
+2.4%
$6.04
+23.6%
-0.7%$550.04M$1.88BN/A4,200
CTEV
Claritev
4.3624 of 5 stars
$27.30
+1.5%
$44.83
+64.2%
-47.2%$462.74M$965.41MN/A3,000
AMWL
American Well
2.5879 of 5 stars
$11.80
-2.0%
$12.30
+4.3%
+176.1%$194.88M$249.32MN/A562
DH
Definitive Healthcare
2.0236 of 5 stars
$1.30
+3.8%
$1.47
+13.4%
-48.5%$139.31M$241.52MN/A686

Related Companies and Tools


This page (NASDAQ:OPRX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners